Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
about
Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes.Opposing Gatekeepers of Apical Sterol Transport: Niemann-Pick C1-Like 1 (NPC1L1) and ATP-Binding Cassette Transporters G5 and G8 (ABCG5/ABCG8)Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss dietAcceleration of biliary cholesterol secretion restores glycemic control and alleviates hypertriglyceridemia in obese db/db mice.A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbitsNPC1L1 and cholesterol transportDietary cholesterol reverses resistance to diet-induced weight gain in mice lacking Niemann-Pick C1-Like 1.Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis.Current status of therapy in nonalcoholic Fatty liver disease.Pathogenesis and therapeutic approaches for non-alcoholic fatty liver diseaseEzetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice.Effects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterol.Effective therapy using voglibose for nonalcoholic steatohepatitis in a patient with insufficient dietary and exercise therapy: exploring other treatment possibilities.SREBP2 mediates the modulation of intestinal NPC1L1 expression by curcumin.Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis.Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia.Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome.A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia.Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic ratsProtein mediators of sterol transport across intestinal brush border membrane.Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol.Cholesterol induces lipoprotein lipase expression in a tree shrew (Tupaia belangeri chinensis) model of non-alcoholic fatty liver disease.Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis.Nutrition therapy for liver diseases based on the status of nutritional intake.Impact of ezetimibe on atherosclerosis: is the jury still out?Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes.Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia.Bisphenol A promotes cholesterol absorption in Caco-2 cells by up-regulation of NPC1L1 expression.Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease.Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs.Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.New insights into the molecular mechanism of intestinal fatty acid absorption.Current therapeutic strategies in non-alcoholic fatty liver disease.Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.Intestinal and hepatic niemann-pick c1-like 1.
P2860
Q27007515-FBC2E404-8D05-4D1E-906F-4DACB76810A7Q30413592-270D4104-F181-4BCC-992C-DC4E8FC6D16BQ33609823-194828FF-684C-4F5D-9CAD-C033E1CB13E6Q33668002-585A92F9-DED1-4FF2-BB19-B962C7BA23EAQ33755566-98C306CF-2BD5-46DE-99F2-6E830C72C4EDQ33761680-A18A8738-27AE-4DB3-8F44-29855E556102Q33804734-F8D3B783-FF32-4964-AC56-1DDC563751D7Q33894773-EE9D2130-BB07-4410-BD70-0C57C43B4CCEQ33947195-1664E415-15BA-4930-AB1A-AC8D4F193BA0Q34019608-FF928915-F77F-49C3-9B27-E47737EED7EBQ34116347-AF1FC9F8-9013-4596-9F52-F1E303EB900BQ34187966-888EF6B3-75C6-49A0-B754-5E93D9BD146DQ34408961-CFB1501D-2729-48DB-B435-3D83619A2F57Q34449857-D917C83F-3A5E-4221-8F1C-781A778CADEFQ34487963-E02BF356-3A7B-4515-BE09-715E11F8FF4CQ34955169-AD68DB8B-CD21-4476-9AF2-1F0CD2610A3CQ35071369-63A767D0-424B-46B2-9DEC-CE4CF9ECEE3CQ35087116-1A693105-F3BA-4B02-A09D-6082B015489FQ35474335-16DD88A5-37B3-4F88-8800-5371598B3CD3Q35562193-0359E277-4669-4D5D-A63E-C2508A1ACA7DQ35571839-769CF6F3-08B5-4220-A638-8E6AC045972EQ35669490-19E5A234-412F-4324-A981-85A84B72A4C2Q35819533-B6418972-3141-491C-B8B3-DBE07896E8BFQ35838266-5878F9B0-78DD-4CDD-B1F3-514050E6308BQ35895832-B85EA7DE-06BF-45B4-883A-869263893E03Q36237764-D1F4A63E-415A-4EEE-813B-0B3AEDE8BE97Q36296929-4B957EEF-B2AA-4383-9AE6-74534EF6FD39Q36417913-65350121-D8D9-4E8A-8A57-4E9AB65AFD94Q37151389-72FB8111-BD4E-4CDC-9556-D56D7EA75671Q37361667-03E206B4-CBEE-4A47-ADBA-A815A985135EQ37402089-3BA3A4DF-FC46-43C0-87A1-7E0F8FD8E133Q37567209-750F0E7D-2D29-4383-A197-8906B0DC4F85Q37604513-10609C17-9083-4A57-ADF4-5A7EF3D5ECD4Q37613264-5CE9AE8E-5CA4-4062-AC72-FEF015ED2B2FQ37620806-1808C600-5BB8-4B8E-AFC6-E7997C1AE29FQ37662878-5B5C005D-A26B-4266-B67E-EA8700C883F7Q37718704-BFE31550-637A-4C8A-B901-58E9AF438184Q37859419-31CF197B-B8E6-4791-8A43-6BA96DC92500Q37978785-581B44AD-FBAB-4D9A-8978-497B6B7C3FD9Q38132749-8023F5EA-A152-42B4-8865-787D0DE82EBB
P2860
Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Ezetimibe improves liver steat ...... t model of metabolic syndrome.
@en
Ezetimibe improves liver steat ...... t model of metabolic syndrome.
@nl
type
label
Ezetimibe improves liver steat ...... t model of metabolic syndrome.
@en
Ezetimibe improves liver steat ...... t model of metabolic syndrome.
@nl
prefLabel
Ezetimibe improves liver steat ...... t model of metabolic syndrome.
@en
Ezetimibe improves liver steat ...... t model of metabolic syndrome.
@nl
P2093
P2860
P921
P1433
P1476
Ezetimibe improves liver steat ...... t model of metabolic syndrome.
@en
P2093
Akio Kawakami
Hideto Ishii
Masayuki Yoshida
Michiyo Deushi
Mihoko Haraguchi
Mitsunori Nomura
Mitsuyo Okazaki
Mizuho Ito
P2860
P304
P356
10.1016/J.FEBSLET.2007.11.023
P407
P577
2007-11-20T00:00:00Z